# Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment

Source: https://onco.cc/roadmaps/nutrition-lifestyle-roadmap/  
OnCo record `nutrition-lifestyle-roadmap` (Roadmap). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

What people eat, weigh and do shapes who gets cancer and how treatment goes. Decades of trials separated what is established (obesity, alcohol and inactivity cause cancer; exercise after treatment reduces recurrence) from what is hype, and the next questions are being asked with the rigour of a drug trial.

## Summary

Epidemiology established the causes: tobacco, then excess body fat (now linked to at least thirteen cancers), alcohol, processed meat and physical inactivity. The first generation of intervention trials mostly disappointed. A vegetable-rich diet did not reduce breast cancer recurrence (WHEL), vitamin D and fish oil did not prevent cancer (VITAL), fish oil did not slow cachexia, and high-dose vitamin C did not treat anything. Those null results are as valuable as positive ones: they are why this front can tell evidence from marketing.

The breakthrough came from exercise. In 2025 the CHALLENGE trial showed that a coached, structured exercise programme after colon cancer treatment reduces recurrence and improves survival, the first randomised proof that a lifestyle intervention changes a hard cancer outcome. Nutrition care during treatment has its own evidence base: malnutrition screening, dietitian-led therapy, enhanced recovery around surgery and prehabilitation are all in guidelines. The live scientific questions are the gut microbiome's effect on immunotherapy, whether GLP-1 agonists and bariatric surgery prevent cancer, whether fasting or ketogenic diets help around treatment, and how to treat cachexia as a disease.

The pace is set by the absence of a commercial sponsor for anything that cannot be patented, by misinformation that fills the gap, and by health systems that do not pay for exercise or dietetics the way they pay for drugs.

## Fields

- Kind: Roadmap
- Last checked: 2026-09-10

## Sources

- CHALLENGE trial (NEJM 2025): https://www.nejm.org/doi/full/10.1056/NEJMoa2502760
- IARC: body fatness and cancer (NEJM 2016): https://www.nejm.org/doi/full/10.1056/NEJMsr1606602

## Connected records

- ideas: [A dose-finding trial for exercise after cancer](https://onco.cc/ideas/idea-nl-exercise-dose-finding/), [A trial of GLP-1 weight-loss drugs with cancer as the primary outcome](https://onco.cc/ideas/idea-prev-glp1-cancer-prevention-rct/), [Cancer warnings on alcohol labels, evaluated as a natural experiment](https://onco.cc/ideas/idea-prev-alcohol-cancer-warning-labels/), [Combine the new anti-wasting antibody with exercise and protein](https://onco.cc/ideas/idea-bio2-gdf15-plus-exercise/), [Evidence-based integrative oncology in every cancer centre to meet demand safely](https://onco.cc/ideas/idea-moon-integrative-oncology-bridge/), [Four weeks of training and nutrition before major cancer surgery, as standard](https://onco.cc/ideas/idea-bio2-prehabilitation-standard/), [Fund structured exercise after colon cancer surgery as a treatment, because a randomised trial says it works as well as a drug](https://onco.cc/ideas/idea-crc-exercise-as-a-funded-treatment/), [GLP-1 drugs to reverse endometrial precancer in women with obesity](https://onco.cc/ideas/idea-prev-glp1-endometrial-hyperplasia/), [Minimum alcohol pricing evaluated with cancer endpoints](https://onco.cc/ideas/idea-prev-minimum-unit-pricing-cancer-endpoints/), [Pay for supervised exercise the way we pay for drugs](https://onco.cc/ideas/idea-bio2-exercise-reimbursement/), [Structured exercise prescribed like a drug in all curative-intent cancer care](https://onco.cc/ideas/idea-exercise-as-adjuvant/), [Treat cachexia before it starts](https://onco.cc/ideas/idea-cachexia-gdf15-prevention/), [Treat insomnia in survivors and measure whether the cancer notices](https://onco.cc/ideas/idea-nl-sleep-circadian-survivorship-rct/)
- companies: [Canadian Cancer Trials Group (CCTG)](https://onco.cc/companies/cctg/), [MaaT Pharma](https://onco.cc/companies/maat-pharma/)
- roadmaps: [Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers](https://onco.cc/roadmaps/prevention-roadmap/), [Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it](https://onco.cc/roadmaps/rejuvenation-roadmap/), [Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards](https://onco.cc/roadmaps/survivorship-roadmap/)
- fronts: [Diet, Exercise & Lifestyle](https://onco.cc/fronts/nutrition-lifestyle/)
- technologies: [Alcohol reduction, pricing and cancer warning labels](https://onco.cc/technologies/alcohol-reduction-labelling/), [Bariatric surgery and cancer incidence](https://onco.cc/technologies/bariatric-surgery-cancer-incidence/), [Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine](https://onco.cc/technologies/cachexia-appetite-pharmacotherapy/), [Cachexia-directed therapy (GDF-15 blockade)](https://onco.cc/technologies/cachexia-therapy/), [Dietary fibre and the gut microbiome for immunotherapy response](https://onco.cc/technologies/dietary-fibre-microbiome-io/), [Dietary supplements during cancer treatment: interactions and harms](https://onco.cc/technologies/dietary-supplements-treatment-interactions/), [Dietitian-led weight-loss programmes in HR-positive breast cancer](https://onco.cc/technologies/dietitian-led-weight-loss-breast/), [Enhanced recovery (ERAS) and perioperative nutrition](https://onco.cc/technologies/eras-perioperative-nutrition/), [Enteral and parenteral nutrition support](https://onco.cc/technologies/enteral-parenteral-nutrition/), [Evidence-based integrative oncology](https://onco.cc/technologies/integrative-oncology/), [Exercise & lifestyle oncology](https://onco.cc/technologies/exercise-oncology/), [Exercise during chemotherapy and radiotherapy](https://onco.cc/technologies/exercise-during-chemotherapy/), [Faecal microbiota transplantation for PD-1 non-responders](https://onco.cc/technologies/fmt-checkpoint-nonresponders/), [Fasting and fasting-mimicking diets around chemotherapy](https://onco.cc/technologies/fasting-mimicking-diet/), [Fish oil (EPA) for cancer weight loss](https://onco.cc/technologies/omega3-epa-cachexia/), [GLP-1 receptor agonists and obesity-related cancer risk](https://onco.cc/technologies/glp1-agonists-cancer-risk/), [High-dose intravenous vitamin C](https://onco.cc/technologies/high-dose-vitamin-c/), [Immunonutrition before cancer surgery](https://onco.cc/technologies/immunonutrition-perioperative/), [Ketogenic diets in glioblastoma](https://onco.cc/technologies/ketogenic-diet-glioblastoma/), [Mediterranean and plant-forward dietary patterns](https://onco.cc/technologies/mediterranean-plant-forward-diet/), [Microbiome modulation to unlock immunotherapy](https://onco.cc/technologies/microbiome-modulation-io/), [Nutrition support and cachexia management](https://onco.cc/technologies/oncology-nutrition/), [Oncology nutrition assessment and medical nutrition therapy](https://onco.cc/technologies/nutrition-screening-mnt/), [Prehabilitation before cancer surgery](https://onco.cc/technologies/prehabilitation/), [Probiotics, antibiotics and stewardship around immunotherapy](https://onco.cc/technologies/probiotics-antibiotic-stewardship-io/), [Red and processed meat reduction](https://onco.cc/technologies/red-processed-meat-reduction/), [Resistance training and protein for cachexia and sarcopenia](https://onco.cc/technologies/resistance-training-cachexia/), [Sleep and circadian interventions in cancer](https://onco.cc/technologies/sleep-circadian-interventions/), [Smoking cessation in cancer patients](https://onco.cc/technologies/smoking-cessation-after-diagnosis/), [Structured exercise programmes after curative treatment](https://onco.cc/technologies/structured-exercise-survivorship/), [Time-restricted eating in cancer prevention and survivorship](https://onco.cc/technologies/time-restricted-eating/), [Ultra-processed food and sugar-sweetened drinks](https://onco.cc/technologies/ultra-processed-food-ssb/), [Vitamin D and omega-3 supplementation](https://onco.cc/technologies/vitamin-d-omega3-supplementation/), [Yoga during and after cancer treatment](https://onco.cc/technologies/yoga-cancer/)
- institutions: [European Society for Clinical Nutrition and Metabolism](https://onco.cc/institutions/espen/), [International Agency for Research on Cancer (IARC / WHO)](https://onco.cc/institutions/iarc/)
- terms: [Cancer cachexia](https://onco.cc/terms/cachexia/), [Dietary pattern scores (Mediterranean, HEI, AHEI, DASH, WCRF/AICR)](https://onco.cc/terms/dietary-pattern-scores/), [Gut microbiome diversity and composition](https://onco.cc/terms/gut-microbiome-diversity/), [Malnutrition screening tools (MUST, NRS-2002, MST, PG-SGA)](https://onco.cc/terms/malnutrition-screening/), [Metabolic syndrome and insulin resistance](https://onco.cc/terms/metabolic-syndrome/), [Obesity-related cancers (IARC list of 13)](https://onco.cc/terms/obesity-related-cancers/), [Risk factor](https://onco.cc/terms/risk-factor/), [Sarcopenia](https://onco.cc/terms/sarcopenia/), [Unproven diet claims (alkaline, juice, 'anti-cancer' diets)](https://onco.cc/terms/unproven-diet-claims/), [Warburg-effect diet claims ('sugar feeds cancer')](https://onco.cc/terms/warburg-effect-diet-claims/)
- trials: [BWEL (Breast Cancer Weight Loss, Alliance A011401)](https://onco.cc/trials/bwel/), [CHALLENGE (CCTG CO.21)](https://onco.cc/trials/challenge/), [ERGO2: ketogenic diet and fasting during re-irradiation of recurrent glioma](https://onco.cc/trials/ergo2/), [FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)](https://onco.cc/trials/fmt-pd1-refractory-melanoma-pitt/), [Low-dose olanzapine for cancer anorexia (Tata Memorial)](https://onco.cc/trials/olanzapine-appetite-tmh/), [MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma](https://onco.cc/trials/mimic-01/), [Ponsegromab phase 2 in cancer cachexia](https://onco.cc/trials/ponsegromab-phase-2/), [PREHAB: multimodal prehabilitation before colorectal cancer surgery](https://onco.cc/trials/prehab-trial/), [VITAL (VITamin D and OmegA-3 TriaL)](https://onco.cc/trials/vital/), [WHEL (Women's Healthy Eating and Living)](https://onco.cc/trials/whel/)
- bottlenecks: [Cachexia, toxicity and the limits of the patient](https://onco.cc/bottlenecks/b-cachexia-supportive/), [Funding follows fashion, not burden](https://onco.cc/bottlenecks/b-funding-allocation/), [Misinformation and unproven therapies](https://onco.cc/bottlenecks/b-misinformation/), [No incentive to repurpose cheap drugs](https://onco.cc/bottlenecks/b-generic-repurposing/), [Prevention we already have is not deployed](https://onco.cc/bottlenecks/b-prevention-adoption/)
- key papers: [Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease](https://onco.cc/key-papers/paper-caret-beta-carotene-retinol-lung-cancer-nejm-1996/)

---
JSON: https://onco.cc/api/v1/entities/nutrition-lifestyle-roadmap.json